Protocol for the Therapy Personalisation Using Multiomic Analyses in Inflammatory Bowel Disease (THAMES‐IBD) Study

What To Know

This is the protocol (study design) for THAMES‑IBD, a multicentre prospective observational cohort that will recruit adults with active ulcerative colitis who are starting or switching advanced therapies, along with inactive UC patients and non‑IBD controls.

The study will collect stool, blood and mucosal biopsy samples for multiomic analyses (metagenomics, metabolomics, transcriptomics, proteomics) plus clinical, dietary and psychosocial data at baseline, 8–14 weeks and 28–32 weeks.

Outcomes will use patient‑reported PRO‑2 scores and biochemical measures, and predictive models will be built using integrated multiomics with internal cross‑validation and, where possible, external validation.

The protocol’s goal is to identify biological mechanisms and predictive biomarkers of response versus nonresponse to advanced therapies in UC to support precision medicine and reduce ineffective treatment cycling. This brief is grounded in the article abstract (study protocol) provided by the journal; Cure8 has not reviewed full study data or results.

Practical note: this is a study design—no results are reported here. If the study completes and validates predictors, findings could affect how clinicians choose advanced therapies, but patients should wait for published results and independent validation before changing treatment.